Cite
Taipale K, Tähtinen S, Havunen R, et al. Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients. Oncotarget. 2018;9(5):6320-6335doi: 10.18632/oncotarget.23967.
Taipale, K., Tähtinen, S., Havunen, R., Koski, A., Liikanen, I., Pakarinen, P., Koivisto-Korander, R., Kankainen, M., Joensuu, T., Kanerva, A., & Hemminki, A. (2018). Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients. Oncotarget, 9(5), 6320-6335. https://doi.org/10.18632/oncotarget.23967
Taipale, Kristian, et al. "Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients." Oncotarget vol. 9,5 (2018): 6320-6335. doi: https://doi.org/10.18632/oncotarget.23967
Taipale K, Tähtinen S, Havunen R, Koski A, Liikanen I, Pakarinen P, Koivisto-Korander R, Kankainen M, Joensuu T, Kanerva A, Hemminki A. Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients. Oncotarget. 2018 Jan 05;9(5):6320-6335. doi: 10.18632/oncotarget.23967. eCollection 2018 Jan 19. PMID: 29464075; PMCID: PMC5814215.
Copy
Download .nbib